Mitra Biotech, a Massachusetts based company, will use its CANscript platform to advance Glenmark’s portfolio. CANscript is an immune-relevant ex vivo platform that allows developers to understand how a drug performs in human tissue.
The platform allows for promising candidates to be prioritized for advancement into clinical trials.
The platform’s response predictions have a high correlation to clinical outcomes. According to Mitra, 90% of the validations CANscript has completed, have demonstrated an overall correlation between the treatment predictions and outcomes.
Mitra stated that CANscript can also give an indication of effective treatments to best inform physicians, and expedite the drug research and development process in an aim to eliminate lost-time and the expenses associated with ineffective treatments.
In a press release Venkat Reddy, senior VP and global head of translation sciences at Glenmark said, “We are pleased to have access to proprietary technology from Mitra to assist us in accelerating understanding of the clinical relevance and potential utility of our T cell engagers (GBR1302 and GBR1342) in human biopsies.”
Glenmark’s pipeline that will be tested includes three bispecific monoclonal antibody candidates that are being studied in a wide range of tumor types.
Glenmark and Mitra were unable to provide further comment at this time.